Business Development Deal Architecture
  • Search OnBioBD:

  • OnBioBD OldSkool NEWS:

    - OnBioVC 4Q11 Trend Analysis, now available
    - OnBioVC 1Q12 White Paper, now available
    - OnBioVC 1Q12 Trend Analysis, coming soon

  • FDA Registered Contract Manufacturer

NewBridge Pharmaceuticals (San Francisco, CA) a commercial-stage biopharmaceutical company focused on oncology, GI and metabolic disorders, closed a $12M Series B financing. Participants include Kuwait Life Sciences Company and Burrill & Co.

Rhythm Pharmaceuticals (Boston, MA) a clinical-stage small peptide company focused on diabetes, obesity and GI disorders, closed a $19M Series A financing, bringing the total round to $40M. Participants include MPM Capital, New Enterprise Associates and Third Rock Ventures.

Logical Therapeutics (Waltham, MA) a clinical-stage biopharmaceutical company focused on rheumatoid arthritis, osteoarthritis, ankalosing spondylitis and other inflammatory diseasea, closed a $16.9M Series C financing. Participants include SV Life Sciences, Burrill & Company, Novo Ventures and Novitas Capital.

Rhythm Pharmaceuticals (Boston, MA) a clinical-stage biopharmaceutical company whose peptide therapeutic agonists are focused on metabolic disorders, closed a $10M Series A financing. Participants include MPM Capital and New Enterprise Associates.

Cellerix (Spain) a clinical-stage biopharma company focused on adult stem cell therapies for Crohn’s and other GI diseases, closed a $37.7M Series C financing. Participants include Ysios Capital Partners, Ventech, Roche Venture Fund and Novartis Venture Fund. Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Alvine Pharmaceuticals (San Carlos, CA) a clinical-stage biopharmaceutical company focused on autoimmune related GI disease such as Celiac disease, closed a $21.5M financing bringing the total round to $47.5M. Participants include Panorama Capital, InterWest Partners, Prospect Venture Partners, Sofinnova Ventures, Black River Asset Management and Flagship Ventures.

Hyperion Therapeutics (San Francisco, CA) a clinical-stage specialty pharmaceutical company focused on gastroenterology and hepatology, closed a $60M Series C financing. Participants include Bay City Capital, Panorama Capital, Highland Capital Partners, New Enterprise Associates, Sofinnova Ventures, and WRF Capital.

ActoGeniX (Belgium) a clinical-stage biopharmaceutical company focused on the development of protein therapeutics for the treatment of gastrointestinal and metabolic diseases, closed a $17.1M Series B financing. Participants include Biovest, Gimv, Biotech Fund Flanders, Baekeland Fund, VIB, LSP, Aescap Venture and Ventech.

Baronova (Goleta, CA) developer of medical devices for the treatment of obesity, closed a $7.5M Series B financing. Participants include Allergan, Arboretum Ventures, Highland Capital Partners and Onset Ventures.

ACT Biotech (San Francisco, CA) focused on developing and commercializing targeted oral and GI cancer drugs, closed a $12M Series A financing. Participants include NGN Capital.

Albireo Pharma (Sweden) focused on developing therapies in the GI and chronic constipation, closed a $40M Series financing. Participants include Nomura Phase4 Ventures, TVM Capital Scottish Widows Investment Partnership and TPG Growth.

Ocera Therapeutics (San Diego, CA) a clinical stage company focused on gastrointestinal and liver diseases closed a $35.5M Series C financing. Participants include Montagu Newhall Associates, InterWest Partners, AgeChem Venture Fund, Cross Creek Capital, FinTech, CDIB BioScience, Domain Associates, Sofinnova Ventures and Thomas, McNerney & Partners.

Gelsis (Boston, MA) is developing a breakthrough treatment for obesity and other gastrointestinal disorders has closed a $16M Series A. Participants include OrbiMed, Queensland BioCapital Funds, PureTech Ventures, Lansing Brown Investments and the Cape Family Fund.

« Previous Entries  Next Page »

to top of page...